The long QT syndrome and torsade de pointes

PACE - Pacing and Clinical Electrophysiology

Volumn 22, Issue 1 I, 1999, Pages 91-110

  El Sherif, Nabil ^a   Turitto, Gioia ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

Dispersion of repolarization; Long QT syndrome; Molecular biology; Torsade de pointes

Indexed keywords

AMANTADINE; AMIODARONE; ANTHOPLEURIN A; ANTIARRHYTHMIC AGENT; ASTEMIZOLE; BRETYLIUM; CHLORAL HYDRATE; CHLOROQUINE; CISAPRIDE; COTRIMOXAZOLE; DIPHENHYDRAMINE; DISOPYRAMIDE; ERYTHROMYCIN; FLUCONAZOLE; HALOFANTRINE; HALOPERIDOL; INDAPAMIDE; ION CHANNEL; ITRACONAZOLE; KETOCONAZOLE; LITHIUM; PENTAMIDINE; PHENOTHIAZINE DERIVATIVE; PIMOZIDE; PROBUCOL; PROCAINAMIDE; QUINIDINE; QUININE; SOTALOL; TACROLIMUS; TERFENADINE; TRICYCLIC ANTIDEPRESSANT AGENT; VASOPRESSIN;

CHROMOSOME ANALYSIS; CLINICAL ARTICLE; DEFIBRILLATOR; DRUG ACTIVITY; ENZYME INHIBITION; GENE EXPRESSION; GENETIC ANALYSIS; GENOTYPE; HEART REPOLARIZATION; HUMAN; ION CURRENT; LONG QT SYNDROME; PREDICTION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SYMPATHECTOMY; TORSADE DES POINTES;

ANIMALS; AUTONOMIC NERVOUS SYSTEM; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGY; HUMANS; ION CHANNELS; LONG QT SYNDROME; TORSADES DE POINTES; VENTRICULAR FIBRILLATION;

EID: 0032957468     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8159.1999.tb00305.x     Document Type: Review

References (75)

1. El-Sherif N, Craelius W, Boutjdir M, et al. Early afterdepolarizations and arrhythmogenesis. J Cardiovasc Electrophysiol 1990; 1:145-160.
2. Antzelevich C, Sicouri S. Clinical relevance of cardiac arrhythmias generated by afterdepolarizations: Role of M cells in the generation of U waves, triggered activity and torsade de pointes. J Am Coll Cardiol 1994; 23:259-277.
3. El-Sherif N, Caref EB, Yin H, et al. The electrophysiological mechanism of ventricular tachyarrhythmias in the long QT syndrome: Tridimensional mapping of activation and recovery patterns. Circ Res 1996; 79:474-492.
4. Dessertenne F. La tachycardie ventriculaire a deux foyers opposes variables. Arch Mal Coeur 1996; 59:263-272.
5. Roden DM, Lazzara R, Rosen M, et al. Multiple mechanisms in the long QT syndrome. Current knowledge, gaps, and future directions. Circulation 1996; 94:1996-2012.
6. Jackman WM, Clark M, Friday KJ, et al. Ventricular tachyarrhythmias in the long QT syndrome. Med Clin North Am 1984; 68:1079-1104.
7. Leenhardt A, Glaser E, Burguera M, et al. Short-coupled variant of torsade de pointes. A new electrocardiographic entity in the spectrum of idiopathic ventricular tachyarrhythmias. Circulation 1994; 89:206-215.
8. El-Sherif N. Proarrhythmic consequences of pharmacologically prolonged repolarization: Experimental considerations. In BN Singh, HJJ Wellens, M Hiraoka (eds.): Pharmacological Control of Cardiac Arrhythmias: To Delay Conduction or to Prolong Refractoriness? Armonk, NY, Futura Publishing Co. Inc., 1994, pp. 335-356.
9. Vincent GM. The molecular basis of the long QT syndrome: Genes causing fainting and sudden death. Ann Rev Med 1998; 49:263-274.
10. Wang Q, Curran ME, Splawski I, et al. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet 1996; 12:17-23.
11. ks cardiac potassium current. Nature 1996; 384: 78-80.
12. ks potassium channel. Nature 1996; 384:80-83.
13. Curran ME, Splawski I, Timothy KW, et al. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995; 80: 795-803.
14. Wang Q, Shen J, Splawski I, et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995; 80:805-811.
15. Sanguinetti MC, Jiang C, Curran ME, et al. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the Ikr potassium channel. Cell 1995; 81:299-307.
16. Schott JJ, Charpentier F, Peltier S, et al. Mapping of a gene for long QT syndrome to chromosome 4q25-27. Am J Hum Genet 1995; 57:1114-1122.
17. Neyroud N, Tesson F, Denjoy I, et al. A novel mutation in the potassium channel gene KVLQT1 causes the Jervell and Lange-Nielsen cardioauditory syndrome. Nat Gen 1997; 15:186-189.
18. Rubie C, Hordt M, Towbin JA, et al. KCNE1 mutations cause Jervell and Lange-Nielsen syndrome. Nat Gen 1997; 17:267-268.
19. Canadian Adverse Drug Reaction Newsletter. Drugs causing prolongation of QT interval and torsade de pointes. Can Med Assoc J 1998; 158: 103-104.
20. El-Sherif N, Zeiler RH, Craelius W, et al. QTU prolongation and polymorphic ventricular tachyarrhythmias due to bradycardia-dependent early afterdepolarizations. Circ Res 1988; 63:286-305.
21. Boutjdir M, El-Sherif N. Pharmacological evaluation of early afterdepolarisations induced by sea anemone toxin (ATXII) in dog heart. Cardiovasc Res 1991; 25:815-819.
22. El-Sherif N, Fozzard HA, Hanck DA. Dose-dependent modulation of the cardiac sodium channel by the sea anemone toxin ATXII. Circ Res 1992; 70:285-301.
23. Boutjdir M, Restivo M, Wei Y, et al. Early afterdepolarization formation in cardiac myocytes: Analysis of phase plane patterns, action potential, and membrane currents. J Cardiovasc Electrophysiol 1994; 5:609-620.
24. Bennett PB, Yazawa K, Makita N, et al. Molecular mechanism for an inherited cardiac arrhythmia. Nature 1995; 376:683-685.
25. El-Sherif N, Chinushi M, Caref EB, et al. Electrophysiological mechanism of the characteristic electrocardiographic morphology of torsade de pointes tachyarrhythmias in the long QT syndrome. Detailed analysis of ventricular tridimensional activation patterns. Circulation 1997; 96:4392-4399.
26. Haws CW, Lux RL. Correlation between in vivo transmembrane action potential durations and activation recovery intervals from electrograms: Effects of interventions that alter repolarization time. Circulation 1991; 81:281-288.
27. Antzelevitch C, Sicouri S, Litovsky SH, et al. Heterogeneity within the ventricular wall: Electrophysiology and pharmacology of epicardial, endocardial, and M cells. Circ Res 1991; 69:1427-1449.
28. Sicouri S, Antzelevitch C. Electrophysiologic characteristics of M cells in the canine left ventricular free wall. J Cardiovasc Electrophysiol 1995; 6:591-603.
29. Fast VG, Kleber AG. Block of impulse propagation at an abrupt tissue expansion: Evaluation of the critical strand diameter in a 2- and 3-dimensional computer models. Cardiovasc Res 1995; 30: 449-459.
30. Leclerq JF, Maison-Blanche P, Cauchemez B, et al. Respective role of sympathetic tone and cardiac pauses in the genesis of 62 cases of ventricular fibrillation recorded during Holter monitoring. Eur Heart J 1988; 9:1276-1283.
31. Viskin S, Alla SR, Barron HV, et al. Mode of onset of torsades de pointes in congenital long QT syndrome. J Am Coll Cardiol 1996; 28:1262-1268.
32. Roden DM, Woosley RL, Primm RK. Incidence and clinical features of the quinidine associated long QT syndrome: Implications for patient care. Am Heart J 1986; 111:1088-1093.
33. Kay GN, Plumb VJ, Arciniegas JG, et al. Torsades de pointes; the long-short initiating sequence and other clinical features; observations in 32 patients. J Am Coll Cardiol 1990; 2:806-817.
34. El-Sherif N, Chinushi M, Restivo M, et al. Electrophysiologic basis of the arrhythmogenicity of short-long cardiac sequences that precede ventricular tachyarrhythmias in the long QT syndrome, (abstract) PACE 1998; 21:852.
35. Schwartz PJ, Malliani A. Electrical alternation of the T-wave: Clinical and experimental evidence of its relationship with the sympathetic nervous system and with the long Q-T syndrome. Am Heart J 1975; 89:45-50.
36. Habbab MA, El-Sherif N. TU alternans, long QTU, and torsade de pointes: Clinical and experimental observations. PACE 1992; 15:916-931.
37. Moss AJ. Long QT syndrome. In PJ Podrid, PR Kowey (eds.): Cardiac Arrhythmias. Mechanisms, Diagnosis, and Management. Baltimore, MD, Williams & Wilkins, 1995, pp. 1110-1120.
38. Surawicz B, Fisch C. Cardiac alternans: Diverse mechanisms and clinical manifestations. J Am Coll Cardiol 1992; 20:483-499.
39. Verrier RL, Nearing BD. Electrophysiologic basis for T wave alternans as an index of vulnerability to ventricular fibrillation. J Cardiovasc Electrophysiol 1994; 5:445-461.
40. Rosenbaum DS, Jackson LE, Smith GM, et al. Electrical alternans and vulnerability to ventricular arrhythmias. N Engl J Med 1994; 330:235-241.
41. Chinushi M, Restivo M, Caref EB, et al. Electrophysiological basis of the arrhythmogenicity of QT/T alternans in the long QT syndrome: Tridimensional analysis of the kinetics of cardiac repolarization. Circ Res 1998; 83:614-628.
42. Schwartz PJ, Locati E, Priori SG, et al. The long QT syndrome. In DP Zipes, J Jalife (eds.): Cardiac Electrophysiology: From Cell to Bedside. Philadelphia, PA, WB Saunders Co., 1990, pp. 589-605.
43. Yanowitz R, Preston JB, Abildskov JA. Functional distribution of right and left stellate innervation to the ventricles: Production of neurogenic electrocardiographic changes by unilateral alteration of sympathetic tone. Circ Res 1966; 18:416-428.
44. Abildskov JA. Adrenergic effects on the QT interval of the electrocardiogram. Am Heart J 1976; 92:210-216.
45. Ben David J, Zipes DP. Differential response to right and left ansae subclaviae stimulation of early afterdepolarizations and ventricular tachycardia induced by cesium in dogs. Circulation 1988; 78:1241-1250.
46. Ben David J, Zipes DP. Alpha adrenoceptor stimulation and blockade modulates cesium-induced early afterdepolarizations and ventricular tachyarrhythmias in dogs. Circulation 1990; 82: 225-233.
47. Carlsson L, Almgren O, Duker G. QTU-prolongation and torsade de pointes induced by putative Class III antiarrhythmic agents in the rabbit: Etiology and interventions. J Cardiovasc Pharmacol 1990; 16:276-285.
48. Dhein S, Gerwin R, Ziskoven V, et al. Propranolol unmasks Class III like electrophysiological properties of norepinephrine. Arch Pharmacol 1993; 348:643-649.
49. Kolb HA, Somogyi R. Biochemical and biophysical analysis of cell-to-cell channels and regulation of gap junctional permeability. Rev Physiol Biochem Pharmacol 1991; 118:1-48.
50. Schwartz PJ, Priori SG, Locati EH, et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation 1995; 92:3381-3386.
51. Schreick J, Wang Y, Gjini V, et al. Differential effect of β-adrenergic stimulation on the frequency-dependent electrophysiologic actions of the new Class III antiarrhythmics dofetilide, ambasilide, and chromanol 293B. J Cardiovasc Electrophysiol 1997; 8:1420-1430.
52. Vincent GM, Timothy K, Leppert M, et al. The spectrum of symptoms and QT interval in carriers of the gene for the long-QT syndrome. N Engl J Med 1992; 327:846-852.
53. Moss AJ, Schwartz PJ, Crampton RS, et al. The long QT syndrome: Prospective longitudinal study of 328 families. Circulation 1991; 84:1136-1144.
54. Vincent GM, Fox J, Zhang L, et al. Beta-blockers markedly reduce risk and syncope in KVLQT1 long QT patients. Circulation 1996; 94(Suppl. 1):I-204.
55. Schwartz PJ, Locati EH, Napolitano C, et al. The long QT syndrome. In DP Zipes, J Jalife (eds.): Cardiac Electrophysiology: From Cell to Bedside. 2nd ed. Philadelphia, PA, WB Saunders, 1995, pp. 788-811.
56. Hayoun B, Lupoglazoff JM, Magnier S, et al. Congenital long QT syndrome: An elective indication for beta blocker treatment. Arch Mal Coeur Vaiss 1995; 88:737-742.
57. Compton SJ, Lux RL, Ramsey MR, et al. Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. Circulation 1996; 94:1018-1022.
58. Hallman K, Carlsson L. Prevention of Class III-induced proarrhythmias by flecainide in an animal model of the acquired long QT syndrome. Pharmacol Toxicol 1995; 77:250-254.
59. Chinushi M, Aizawa Y, Furushima H, et al. Nicorandil suppresses a hump on the monophasic action potential and torsade de pointes in a patient with idiopathic long QT syndrome. Jpn Heart J 1995; 36:477-481.
60. Vincent GM, Fox J, Zhang L, et al. Effects of a potassium channel opener in KVLQT1 long QT gene carriers. J Am Coll Cardiol 1997; 29:183A.
61. Sato T, Hata Y, Yamamoto M, et al. Early afterdepolarization abolished by potassium channel opener in a patient with idiopathic long QT syndrome. J Cardiovasc Electrophysiol 1995; 6:279-282.
62. Shimuzu W, Ohe T, Kurita T, et al. Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. J Am Coll Cardiol 1995; 26:1299-1309.
63. Priori SG, Napolitano C, Cantu F, et al. Differential response to Na+ channel blockade, beta-adrenergic stimulation, and rapid pacing in a cellular model mimicking the SCN5A and HERG defects present in the long QT syndrome. Circ Res 1996; 78:1009-1015.
64. El-Sherif N. Early afterdepolarizations and arrhythmogenesis. Experimental and clinical aspects. Arch Mal Coeur 1991; 84:227-234.
65. Bonati V, Rolli A, Botti G. Recording of monophasic action potentials of the right ventricle in long QT syndromes complicated by severe ventricular arrhythmias. Eur Heart J 1983; 4:168-179.
66. El-Sherif N, Bekheit SS, Henkin R. Quinidine-induced long QTU interval and torsades de pointes: Role of bradycardia-dependent early afterdepolarizations. J Am Coll Cardiol 1989; 14:252-257.
67. Habbab MA, El-Sherif N. Drug induced torsades de pointes. Role of early afterdepolarizations and dispersion of repolarization. Am J Med 1990; 89:241-246.
68. Shimuzu W, Ohe T, Kurita T, et al. Early afterdepolarizations induced by isoproterenol in patients with congenital long QT syndrome. Circulation 1991; 84:1915-1923.
69. Franz MR, Bargheer K, Raffenbuel W, et al. Monophasic action potential mapping in human subjects with normal electrocardiograms: Direct evidence of the genesis of the T-wave. Circulation 1987; 73:379-386.
70. Tzivoni D, Keren A, Cohen AM, et al. Magnesium therapy for torsades de pointes. Am J Cardiol 1984; 53:528-530.
71. Wolfe CL, Nibley C, Bandhari A, et al. Polymorphous ventricular tachycardia associated with acute myocardial infarction. Circulation 1991; 84:1543-1551.
72. Masrani K, Cowley C, Bekheit S, et al. Recurrent syncope for over a decade due to idiopathic ventricular fibrillation. Chest 1994; 106:1601-1603.
73. Nademanee K, Veerakul G, Nimmanit S, et al. Arrhythmogenic marker for sudden unexplained death syndrome in Thai men. Circulation 1997; 96:2595-2600.
74. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: A distinct clinical and electrocardiographic syndrome. J Am Coll Cardiol 1992; 20:1391-1396.
75. Chen Q, Kirsch GE, Zhang D, et al. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature 1998; 392:293-296.